Thalia Therapeutics (LSE:THAT) Tariff Resilience Score: 0/10 (As of Jul. 03, 2026)


What is Thalia Therapeutics Tariff Resilience Score?

Thalia Therapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

Thalia Therapeutics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Thalia Therapeutics might have .

Thalia Therapeutics  (LSE:THAT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Thalia Therapeutics Tariff Resilience Score Related Terms

Thalia Therapeutics Business Description

Other Exchanges 0GO:Germany
Address 2 Portman Street, London, GBR, W1H 6DU
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.